EXPRESSION THERAPEUTICS, LLC
Tucker, GA · Biotech · Private
Proprietary platform technologies for optimized therapeutic transgene expression and gene delivery in off-the-shelf allogeneic cell and gene therapies for cancer
expressiontherapeutics.com →- Grants
- $7.0M
- 14 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 32
- 2 granted · 30 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201420162018202020222024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Bioengineered Recombinant FVIII | $673,613 | |
| Federal grant | Department of Health and Human Services · Phase II · Bioengineered factor VIII gene therapy for hemophilia A | $826,775 | |
| Federal grant | Department of Health and Human Services · Phase I · Selection and preclinical validation of a lead candidate liver-directed AAV-FVIII expression cassette | $224,223 | |
| Federal grant | Department of Health and Human Services · Phase I · Selection and preclinical validation of a lead candidate liver-directed AAV-FVIII expression cassette | $224,223 | |
| Federal grant | Department of Health and Human Services · Phase I · Preclinical Evaluation of Ancestral Coagulation Factor VIII | $224,976 | |
| Federal grant | Department of Health and Human Services · Phase I · Preclinical Evaluation of Ancestral Coagulation Factor VIII | $224,976 | |
| Federal grant | Department of Health and Human Services · Phase II · Clinical Testing of the First Suspension BHK-M Cell Platform Derived Biotherapeutic | $747,641 | |
| Federal grant | Department of Health and Human Services · Phase II · Clinical Testing of the First Suspension BHK-M Cell Platform Derived Biotherapeutic | $1,499,692 | |
| Federal grant | Department of Health and Human Services · Phase I · A Microscale Platform for Augmentation of Cell Transduction (MPACT) to Enhance Ex Vivo Gene Transfer | $224,999 | |
| Federal grant | Department of Health and Human Services · Phase I · A Microscale Platform for Augmentation of Cell Transduction (MPACT) to Enhance Ex Vivo Gene Transfer | $224,999 | |
| Federal grant | Department of Health and Human Services · Phase II · Clinical Testing of the First Suspension BHK-M Cell Platform Derived Biotherapeutic | $752,051 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · ADEPT-STAR therapy for high risk neuroblastoma | $400,000 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · ADEPT-STAR therapy for high risk neuroblastoma | $400,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Allogeneic cell and gene therapy for neuroendocrine tumors | $400,000 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2839 | Verve Therapeutics | — | $94M |
| 2840 | Scorpion Therapeutics | — | $297M |
| 2841 | VASCULAR BIOSCIENCES, INC. | — | — |
| 2842 | EXPRESSION THERAPEUTICS, LLC | — | — |
| 2843 | CinCor Pharma | — | $143M |
| 2844 | GRADIENT BIOMODELING, LLC | — | — |
| 2845 | Solid Biosciences | — | $109M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Compositions And Methods For Promoting Hematopoietic Cell Cytotoxicitygranted
- Factor VIII Molecules and Their Useapplication
- Nucleic Acid And Amino Acid Sequences Encoding High-level Expressor Factor Viii Polypeptides And Methods Of Useapplication
- Engineered T Cellsapplication
- Lentiviral Systemapplication
- High yield suspension cell line, system and method for making samegranted
- Engineered T Cellsapplication
- Lentiviral Systemapplication
- Engineered T Cellsapplication
- Engineered T Cellsapplication
- Manufacturing of Cells Genetically Engineered to Express Secreted T Cell Actuatorsapplication
- Manufacturing of Cells Genetically Engineered to Express Secreted T Cell Actuatorsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.